Two articles from today’s Journal, but one topic.
The first looks at the suspicious rise in volume of trades in Allergan prior to disclosure of a takeover bid. Round up the usual suspects. The second raises questions about the SEC’s theory in insider trading cases and whether not only must you know the information is ill-gotten, but you must also get that information in return for something.
So, how you got it matters more than the information. Go figure.